KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Operating Expenses (2018 - 2025)

Historic Operating Expenses for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $83.7 million.

  • Adaptive Biotechnologies' Operating Expenses rose 583.81% to $83.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $330.9 million, marking a year-over-year decrease of 1223.17%. This contributed to the annual value of $341.5 million for FY2024, which is 1404.57% down from last year.
  • As of Q3 2025, Adaptive Biotechnologies' Operating Expenses stood at $83.7 million, which was up 583.81% from $83.9 million recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Operating Expenses peaked at $116.9 million during Q4 2023, and registered a low of $79.1 million during Q3 2024.
  • Over the past 5 years, Adaptive Biotechnologies' median Operating Expenses value was $90.6 million (recorded in 2024), while the average stood at $91.4 million.
  • Per our database at Business Quant, Adaptive Biotechnologies' Operating Expenses skyrocketed by 5246.04% in 2021 and then plummeted by 3042.82% in 2024.
  • Adaptive Biotechnologies' Operating Expenses (Quarter) stood at $99.5 million in 2021, then fell by 5.17% to $94.4 million in 2022, then increased by 23.8% to $116.9 million in 2023, then plummeted by 30.43% to $81.3 million in 2024, then grew by 2.94% to $83.7 million in 2025.
  • Its Operating Expenses stands at $83.7 million for Q3 2025, versus $83.9 million for Q2 2025 and $82.0 million for Q1 2025.